Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.

MLA

Vaclavkova, Andrea, et al. “Oral Ponesimod in Patients with Chronic Plaque Psoriasis: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial.” Lancet (London, England), vol. 384, no. 9959, Dec. 2014, pp. 2036–45. EBSCOhost, https://doi.org/10.1016/S0140-6736(14)60803-5.

APA

Vaclavkova, A., Chimenti, S., Arenberger, P., Holló, P., Sator, P.-G., Burcklen, M., Stefani, M., & D’Ambrosio, D. (2014). Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet (London, England), 384(9959), 2036–2045. https://doi.org/10.1016/S0140-6736(14)60803-5

Chicago

Vaclavkova, Andrea, Sergio Chimenti, Petr Arenberger, Peter Holló, Paul-Gunther Sator, Michel Burcklen, Mylène Stefani, and Daniele D’Ambrosio. 2014. “Oral Ponesimod in Patients with Chronic Plaque Psoriasis: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial.” Lancet (London, England) 384 (9959): 2036–45. doi:10.1016/S0140-6736(14)60803-5.